OncoSec Medical to Present at 24th Annual Wall Street Analyst Forum Institutional Investor Conference
February 25 2014 - 6:02AM
Business Wire
OncoSec Medical Inc. (OTCQB: ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid
tumors, today announced that Punit Dhillon, President and CEO, will
present a corporate overview of the company at the 24th Annual Wall
Street Analyst Forum Institutional Investor Conference at the
University Club in New York, New York on Monday, March 3rd at 12:05
p.m. (EST).
At the time of the presentation, a live webcast of OncoSec’s
presentation will be available at the following link:
http://www.visualwebcaster.com/event.asp?id=98095
OncoSec recommends registering at least 10 minutes prior to the
start of the presentation to ensure timely access. Participants
will require Windows Media Player (a free download is available
from the presentation link) in order to participate. After the
presentation, an archived version of the webcast will be available
on OncoSec’s web page at http://www.oncosec.com under the
“Events” tab.
About the Wall Street Analyst Forum Institutional Investor
Conference
Since 1989, the Wall Street Analyst Forum has conducted over 80
multiday/multitrack analyst conferences in Boston, New York, and
London; in which over 2500 different NYSE/NASDAQ/AMEX/OTC companies
have presented, and over 2000 different institutions have attended.
Analysts and portfolio managers from the vast majority of money
management firms attend its conferences either in person or via
webcast, and past presenters have included such companies as
General Electric, Pfizer, Microsoft Corp, and Mattel. In 1998, WSAF
received extensive coverage in the financial press for conducting
the first live webcast of individual corporate meetings from an
investor conference. The 24th Annual Institutional Investor
Conference will take place March 3-4, 2014 at the University Club
in New York City.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing
its advanced-stage ImmunoPulse immunotherapy to treat solid tumors.
OncoSec Medical's core technology leverages a proprietary
electroporation platform to enhance the local delivery
and uptake of IL-12 and other DNA-based immunocytokines. Clinical
studies of ImmunoPulse have demonstrated positive safety and
preliminary efficacy in the treatment of various skin cancers, as
well as its potential to initiate a systemic immune response
without the toxicities associated with other systemic treatments.
OncoSec's clinical programs currently include three Phase 2
clinical trials targeting metastatic melanoma, Merkel cell
carcinoma and cutaneous T-cell lymphoma. As the company continues
to evaluate ImmunoPulse in these indications, it is also
investigating additional indications as well as efficacious
combination approaches. For more information, please
visit www.oncosec.com.
This press release contains forward-looking statements within
the meaning of the U.S. Private Securities Litigation Reform Act of
1995. Any statements in this release that are not historical facts
may be considered such “forward-looking statements.”
Forward-looking statements are based on management’s current
preliminary expectations and are subject to risks and
uncertainties, which may cause our results to differ materially and
adversely from the statements contained herein. Some of the
potential risks and uncertainties that could cause actual results
to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or
commercialize new products, uncertainties inherent in pre-clinical
studies and clinical trials, unexpected new data, safety and
technical issues, competition, and market conditions. These and
additional risks and uncertainties are more fully described in
OncoSec Medical’s filings with the Securities and Exchange
Commission. Undue reliance should not be placed on forward-looking
statements, which speak only as of the date they are made. OncoSec
Medical disclaims any obligation to update any forward-looking
statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of
unanticipated events.
Investor Relations:OncoSec Medical Inc.Veronica Vallejo,
CFO855-662-6732investors@oncosec.com
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Mar 2024 to Apr 2024
OncoSec Medical (NASDAQ:ONCS)
Historical Stock Chart
From Apr 2023 to Apr 2024